Mankind Pharma Secures Exclusive Rights to Actimed’s Novel Cachexia Treatment

Patent monetization is a great way for companies to grow, especially through patent licensing, where two businesses team up to bring new technologies or treatments to market. Many countries and companies have already used this approach to expand their reach, and now another major deal has joined the list. Actimed Therapeutics Patent Licensing Deal with Mankind Pharma, giving them the rights to develop and sell Actimed’s new drug for cachexia—a serious muscle-wasting condition commonly seen in cancer patients.  Keep reading to find out what this partnership really means and why it matters.

What Is Actimed’s New Cachexia Drug, and How Was the Mankind Pharma Deal Formed?

Before we get into why this licensing deal matters so much, it’s important to understand the drug at the center of it. Actimed Therapeutics’ new drug, S-pindolol benzoate (ACM-001.1), is an experimental treatment developed for cachexia, a severe muscle-wasting condition often seen in cancer and other long-term illnesses. Cachexia causes people to rapidly lose muscle, energy, and weight—and the surprising part is that there’s no approved treatment for it anywhere in the world. That’s why ACM-001.1 has so much potential. It’s designed to help patients maintain muscle strength, slow down muscle breakdown, and improve metabolism, which can make a huge difference during cancer treatment.

This licensing deal with Mankind Pharma became possible because the medical need is massive, and Mankind has the manufacturing strength and distribution network across India and South Asia, actually, to bring this drug to patients. Plus, Mankind was already an investor in Actimed, making the partnership even easier to build. Under the agreement, Mankind now has the right to develop, produce, and sell the drug in India and neighboring countries like Bangladesh, Nepal, Sri Lanka, Myanmar, and Bhutan. At the same time, Actimed provides patents, know-how, and scientific support. Together, their combined strengths speed up the journey toward bringing a much-needed cachexia treatment to millions of patients who currently have no real options.

Read Also: LG and Amazon Finalize Wi-Fi Patent Licensing Agreement

What Are the Key Clauses in the Mankind Pharma and Actimed Therapeutics Patent Licensing Deal?

Now let’s look at the key provisions of this deal and how it’s expected to play out in the future. The Actimed Therapeutics Patent Licensing Deal with Mankind Pharma includes several major clauses that guide how ACM-001.1 will be developed and brought to market across South Asia, such as: 

• To start with, Mankind gets exclusive rights to develop, manufacture, and sell the cachexia drug in India and neighboring countries like Bangladesh, Nepal, Sri Lanka, Bhutan, and Myanmar. 
• Actimed, meanwhile, will supply the patents, scientific know-how, research data, and any future Intellectual property, giving Mankind everything it needs to push the drug through clinical trials and regulatory approvals. 
• Mankind will take on the full responsibility for development costs, local studies, manufacturing, marketing, and distribution, meaning they handle the entire commercial side for the region. 
• This partnership is also strengthened by the fact that Mankind is already an investor in Actimed, which adds trust and makes long-term collaboration smoother. 
• Even though the financial details—like milestone payments or royalties—haven’t been shared publicly, the structure is clear: Actimed brings the innovation, and Mankind brings the scale, making this a strategic partnership aimed at speeding up the delivery of a much-needed cachexia treatment.

Read Also: Understanding Revocation of Patent Licensing and Compulsory Licensing

Conclusion

The Actimed Therapeutics Patent Licensing Deal marks an important step toward bringing a first-of-its-kind cachexia treatment to millions of patients who currently have no effective options. By combining Actimed’s innovative science with Mankind Pharma’s manufacturing strength and regional reach, the deal creates a clear path for faster development, approval and availability of ACM-001.1 across South Asia. If successful, this collaboration could reshape supportive cancer care and set a new benchmark for how licensing agreements can accelerate access to breakthrough therapies.